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Abstract Resumen 
Context: Falsified-medicines pose a worldwide problem to patients, 
healthcare professionals, pharmaceutical companies, and governments. 
Community pharmacists are usually the last points of contact with 
patients and can protect them by quarantining falsified medicines. Hence, 
their opinions are valuable in exploring how the profession can combat 
this. 
Aims: To explore the opinion of pharmacists with respect to falsified 
medicines.  
Methods: A postal survey was developed and distributed to 359 
pharmacies via the local pharmaceutical committee in Hampshire, UK. 
Descriptive statistics and hypothesis testing was conducted. Hypothesis 
testing (95% CI, α = 0.05) will be conducted to identify any gender 
differences, differences based on years of experience and differences 
based on number of working hours per week. 
Results: A 14% response rate was achieved. Pharmacists surveyed believe 
that falsified-medicines pose a significant problem to the profession on a 
five-point Likert scale (4.02 ± 1.078). A pharmacist’s intervention can 
prevent or disrupt the supply to patients (4.12 ± 0.824) and training 
courses can improve pharmacist’s knowledge (4.06 ± 0.843). Pharmacists 
are not confident and capable in identifying falsified-medicines (2.62 ± 
1.105). This is surprising and unexpected because pharmacists are 
medicines-expert. A 10-item scale is validated (72.2% Cronbach alpha). 
Conclusions: Falsified-medicines pose a small but significant and growing 
challenge to the profession. There is underutilization of the high street 
community pharmacist in identifying falsified-medicines. Healthcare 
professionals should report suspect counterfeits to the MHRA.  
Contexto: Los medicamentos falsificados representan un problema 
mundial para los pacientes, los profesionales de la salud, las compañías 
farmacéuticas y los gobiernos. Los farmacéuticos en oficina de farmacia 
son el punto primario de contacto con los pacientes y pueden protegerlos 
detectando falsificaciones. Por lo tanto, sus opiniones son valiosas para 
explorar cómo la profesión puede combatir este problema.  
Objetivos: Explorar la opinión de los farmacéuticos con respecto a los 
medicamentos falsificados. 
Métodos: Se desarrolló una encuesta postal y se distribuyó a 359 farmacias 
a través del comité farmacéutico local en Hampshire, Reino Unido. Se 
realizaron cálculos estadísticos para refutar la hipótesis. Se estableció una 
hipótesis (95% IC, α = 0.05) con respecto a la identificación de 
medicamentos falsos, con diferencias basadas en años de experiencia y 
número de horas de trabajo por semana. 
Resultados: La tasa de respuesta fue del 14%. Los farmacéuticos 
encuestados creen que los medicamentos falsificados representan un 
problema importante para la profesión en una escala de Likert de cinco 
puntos (4.02 ± 1.078). La intervención de un farmacéutico puede prevenir 
o interrumpir el suministro a los pacientes (4.12 ± 0.824) y los cursos de 
capacitación pueden mejorar el conocimiento del farmacéutico (4.06 ± 
0.843). Los farmacéuticos se consideran con limitada capacidad de 
identificar medicamentos falsificados (2.62 ± 1.105). Este resultado 
contrasta con la experiencia y conocimientos que presentan con respecto 
a medicamentos. Se valida una escala de 10 ítems (72.2% alfa de 
Cronbach). 
Conclusiones: Los medicamentos falsificados representan un problema 
creciente para la profesión. Hay una subutilización del farmacéutico de 
oficina de farmacia para identificar medicamentos falsificados. Los 
profesionales de la salud deben ser capaces de identificar y reportar 
falsificaciones sospechosas a los organismos correspondientes.  
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INTRODUCTION 
One of the greatest challenges facing the phar-
maceutical industry today is the international trade 
in counterfeit drugs (Bunker, 2007). Falsified medi-
cines pose a major threat to public health and safe-
ty. As falsifications become more sophisticated, the 
risk that falsified medicines reach patients in the 
UK and European Union (EU) increases every year. 
Falsified medicines represent a serious threat to 
global health and a comprehensive strategy is need-
ed at both the European and international level (Eu-
ropean Commission, 2016). Falsified medicines are prob-
lematic in both primary and secondary care. Falsi-
fied medicines and medical devices are a health risk 
to patients because they circumvent the rigorous 
quality standards required of legitimate manufac-
ture (MHRA, n.d.). The current evidence-based for 
this study is weak as this is an understudied area. 
There is also limited amount of information on the 
extent and prevalence of this problem due to un-
derreporting in the public space by government 
agencies. 
Global spending on medicines is forecast to 
reach nearly $1.3 trillion by 2018, an increase of 
about 30% ($290-320 billion) over the 2013 level, 
driven by population growth, an aging population, 
and improved access in pharmerging countries 
(China, Brazil, India, Russia, Poland, Argentina, 
Turkey, Mexico, Venezuela, Romania, Saudi Arabia, 
Colombia, Vietnam, South Africa, Algeria, Thailand, 
Indonesia, Egypt, Pakistan, Nigeria, and Ukraine) 
markets (Global Outlook for Medicines Through, 2018). The 
prevalence of counterfeit medicines ranges from 
less than 1% of sales in developed countries, to over 
10% in developing countries, depending on the geo-
graphical area (WHO, 2006). The European Commis-
sion estimate that counterfeiting in general, repre-
sents around 5–7% of world trade and as much as 
15% of the global medicines supply chain could, at 
any time, be counterfeit (Feldschreiber, 2009). Counter-
feit medicine seizures by custom officials within the 
EU increased 384% between 2005 and 2006, with a 
further 51% increase in 2007; detentions increased 
by 118% in 2008 (Jackson, 2012). 
According to the Medicines, and Healthcare 
Products Regulatory Agency (MHRA), counterfeit-
ers now also target the most lucrative markets, cop-
ying high-value, high-turnover, high-demand drugs 
(WHO, n.d.). UK is one of several countries targeted 
by counterfeiters because of the potential for huge 
profits in these markets (Jackson et al., 2012). A June 
2015 MHRA report identified £15.8 million seizure in 
global operation targeting counterfeit and unli-
censed medicines and devices (MHRA, 2015). Spurious 
online sale and supply of medicines also contributes 
to the growing danger of falsified medicines. 
Before considering the various elements of the 
problem, the term “falsified medicines” should be 
defined. There is no universally agreed definition of 
counterfeit medicines and jurisdictions around the 
world define counterfeit medicines in many ways. 
The World Health Organization (WHO) currently 
uses the term Substandard, Spurious, Falsely la-
beled, Falsified and Counterfeit (SSFFC) medical 
product until a new definition is agreed upon (WHO, 
2017). The WHO defines counterfeit medication as: 
“A counterfeit medicine is one which is deliberately 
and fraudulently mislabelled with respect to identity 
and/or source. Counterfeiting can apply to both 
branded and generic products and counterfeit prod-
ucts may include products with the correct ingredi-
ents or with the wrong ingredients, without active 
ingredients, with insufficient (inadequate quantities 
of ingredient(s) or with fake packaging”. The WHO 
is a specialized agency of the United Nations that is 
concerned with international public health (WHO, 
1948).  
In the UK, the MHRA (a government agency) at-
tempts to raise awareness and prevent the supply of 
falsified medicines via campaigns, law enforcement 
and investigations. No specific definition of coun-
terfeit medical product exists within English law 
and the MHRA adopts the definition contained 
within the European Falsified Medicines Directive 
(EFMD) (European Commission, 2016). This is stated as 
“Any medicinal product with a false representation 
of: a) its identity, including its packaging, and label-
ing, its name or its composition as regards any of the 
ingredients including excipients and the strength of 
those ingredients; b) its source, including its manu-
facturer, its country of manufacturing, its country of 
origin or its marketing authorization holder; or c) its 
history, including the records and documents relat-
ing to the distribution channels used. The definition 
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does not include unintentional quality defects and is 
without prejudice to infringements of intellectual 
property rights” (MHRA, 2012). 
‘Falsified medicines’ and ‘counterfeit medicines’ 
are terms used to address the deliberate imitation 
of authentic medicine. This study will use the latter 
definition as adopted by the MHRA. 
UK community pharmacists are the final link in 
the supply chain to the patient, and therefore 
pharmacist’s awareness and understanding of falsi-
fied medicines play a crucial role in combating this 
problem. Gaps in the current literature include 
documentation of pharmacist’s opinion and current 
practice regarding falsified medicines in the UK. 
This provides an opportunity to explore the phar-
macist’s role in detecting and responding to coun-
terfeit medication. 
This study explores the opinion of practicing 
pharmacists regarding falsified medicines.  
Hypothesis testing (95% CI, α = 0.05) will be 
conducted to identify any gender differences, any 
differences based on years of registered experience 
and any differences based on number of working 
hours per week. 
MATERIAL AND METHODS 
Literature review 
The following terms were used individually or in 
combination to support the literature review con-
ducted on 7 November 2017: [(pharmacists) AND 
counterfeit medicines] AND falsified medicines in 
PubMed. Doctoral theses were also searched. Three 
articles were identified, which were unrelated to the 
aims of this study. Further hand searching was con-
ducted on the PubMed Central® (PMC) database. 
Due regard has been given to the cultural vari-
ances in adapting these studies. Other studies 
proved inappropriate for inclusion due to their fo-
cus on authentication technologies, significant geo-
graphical, political, economic, and cultural differ-
ences. 
Ethics approval 
University of Portsmouth, School of Pharmacy 
and Biomedical Sciences Ethics Committee ap-
proved this study (Reference number: 08.2016, 
06.12.2016) using the Hampshire local pharmaceuti-
cal committee (LPC) list to invite recruitment. The 
UK Research Integrity Office checklist has been 
used to ensure good practice in research for this 
study (UKRIO Recommended Checklist for Researchers, n.d.). 
Survey questionnaire development 
Two research articles provided the foundation 
for development of the survey questionnaire (Law 
and Youmans, 2011; Shahverdi et al., 2012). Some state-
ments from these surveys were adapted for this 
study and are clearly referenced. This study team 
inserted additional statements. The final instru-
ment contained 11 statements (Table 1) with a 5-
point Likert scale (strongly agree, agree, uncertain, 
disagree, and strongly disagree). 
Questionnaire validation (pretesting) 
The researchers critically appraised the scale in a 
research-team focus-group. This comprised two 
external practicing community pharmacists, sup-
porting academics with recent community and 
hospital practice experience and student members. 
Necessary changes and improvements were made. 
This allowed for detection and deletion of ambigu-
ous words, misinterpretation of questions, poor 
questions, and sensitive questions. Amendments 
and improvements were made to the format, struc-
ture, and content. It took less than 10 minutes to 
complete the final survey. 
Participants recruitment 
Pre-registration and registered pharmacists 
working in community pharmacy in Hampshire, UK 
were invited to recruitment. This included all 
pharmacists in Portsmouth, Southampton, and the 
Isle of Wight (n=359) on the LPC list.  
The postal package was addressed to ‘the phar-
macist’. It included the survey scale, a participant 
information sheet (PIS) and a pre-paid self-
addressed envelope. No personally-identifiable in-
formation was requested or provided, and anonymi-
ty and confidentiality were maintained throughout 
the study. All research data was stored in locked 
cupboards in locked offices and maintained secure-
ly on password protected university encrypted 
computers.  
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Informed consent was assumed once the ques-
tionnaire was completed and returned. The use of 
anonymous results for publication was made clear. 
Responses were invited between December, 2016 – 
January, 2017. Withdrawal would prove difficult as 
no personally-identifiable data was collected and 
this was clearly stated in the PIS. 
 
Table 1. Survey instrument. Summary of scale results. 
 
Statement N 
Results (%) Likert scale 
Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
Mean SD 
1 Falsified medicines pose a significant prob-
lem to the pharmacy profession 
50 2 10 14 32 42 4.02 1.078 
2 Lack of knowledge is a barrier for detecting 
the presence of falsified medicines 
50 2 6 8 44 40 4.14 0.948 
3 Lack of resources is a barrier for detecting 
the presence of falsified medicines 
50 2 12 12 38 36 3.94 1.077 
4 The dispensing pharmacist retains highest 
liability when falsified medicines reach 
patients 
50 6 22 26 18 28 3.40 1.278 
5 A pharmacist’s intervention can prevent or 
disrupt the supply of falsified medicines to 
patients 
50 0 2 22 38 38 4.12 0.824 
6 Training courses can improve pharmacist’s 
knowledge regarding falsified medicines 
50 0 6 14 48 32 4.06 0.843 
7 Listening to patients could help identify 
falsified medicines 
49 4 10 22 44 18 3.63 1.035 
8 The majority of my fellow pharmacists in 
the UK are confident regarding falsified 
medicines 
50 8 24 58 6 4 2.74 0.853 
9 I’m confident and capable in identifying 
falsified medicines 
50 16 32 32 14 6 2.62 1.105 
10 I’m constantly vigilant of encountering 
falsified medicines when checking pre-
scriptions 
50 6 36 20 24 14 3.04 1.195 
11 I have enough knowledge to identify falsi-
fied medicines 
50 16 32 22 24 6 2.72 1.179 
Descriptive Statistics on Likert-scale (1=Strongly Disagree, 2=Disagree, 3=Uncertain, 4=Agree, 5=Strongly Agree). DS: Standard deviation. 
 
Statistical analysis 
Statistical Package for the Social Sciences (SPSS) 
was used to analyze the quantitative data (IBM 
Corp, 2014). Descriptive statistics was used to sum-
marize and describe the data. Hypothesis testing 
was used to draw comparisons and establish rela-
tionships using variables such as gender, years of 
registration, and working hours per week. Non-
parametric tests were used to accept or reject hy-
potheses at 95% confidence interval (α = 0.05). 
 
RESULTS 
A low response rate of 14% (50 out of 359) was 
achieved which may be due to data collection over 
the busiest annual winter festive season. ‘Missing’ 
responses are clearly stated. 
Questions 1 to 4 asked respondents about their 
gender, sector of work, number of registration years 
and working hours per week respectively. Table 2 
summarize this demographics data.  
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Table 2. Pharmacists’ gender and experience. 
  Number of years of registration (years) 
Gender  % (n) Pre-reg. 0 - 1 2 - 3 4 - 5 6 - 7 8+ 
Male 42% (n=21) 1 2 2 1 1 14 
Female 58% (n=29) 1 4 4 4 2 14 
n 50 2 6 6 5 3 28 
Total (%) 100 4 12 12 10 6 56 
 
 
Demographic data  
Males (21, 42%) and females (29, 58%) partici-
pate which accurately describes gender distribution 
within the UK pharmacy population (CfWI, 2013). All 
participants worked in community only, except for 
one (community and hospital). Most respondents 
were registered for 8 or more years, indicating they 
are experienced pharmacists. Most respondents 
worked 35-44 hours a week (mean 36.84 hours, SD 
8.867), however more males worked 45-54 hours a 
week. This study shows both sexes work longer 
hours (Seston and Hassell, 2009). 
Pharmacists’ opinion of falsified medicines 
Respondents were asked to rate the below 
statements on a 5-point Likert-scale (Strongly Disa-
gree, Disagree, Uncertain, Agree, Strongly Agree). 
This data is summarized in Table 1. 
In this study, 74% of respondents believed that 
‘falsified medicines posed a significant problem to 
the profession’ (Statement 1) versus the California 
study, where 59.3% believed it (Law and Youmans, 2011).  
In this study, 84% of respondents believed that a 
‘lack of knowledge is a barrier for detecting the 
presence of falsified medicines’ (statement 2). This 
may indicate shortcomings in available pharmacy 
courses or education. 
‘Lack of resources is a barrier for detecting the 
presence of falsified medicines’ (statement 3) was 
identified by 74% of respondents (36% strongly 
agreed and 38% agreed) versus 82.5% in the Cali-
fornia study (29.2% strongly agreed and 53.3% 
agreed). The lack of resources or skills to detect 
counterfeit medicines has contributed in difficulty 
measuring the extent of the problem in many set-
tings (WHO, 2010).  
‘The dispensing pharmacist retains highest lia-
bility when falsified medicines reach patients’ 
(statement 4) was supported by 46% of respondents 
(28% disagree, 26% uncertain). Approximately half 
of the respondents felt they owed a duty of care to 
the individual patient. The balance of respondents 
may believe that the responsibility should be shared 
between various groups, such as other healthcare 
professionals, regulatory bodies, and the govern-
ment. The largest standard deviation (1.28), indi-
cates a wide spread of opinion. 
‘A pharmacist’s intervention can prevent or dis-
rupt the supply of falsified medicines to patients’ 
(statement 5) was supported by 76% of respond-
ents. This has a narrow standard deviation (0.824) 
indicating consensus around ‘Agree’. As pharma-
cists are usually the last point of contact with pa-
tients in the UK, the respondents may feel that they 
can prevent falsified medicines reaching the public.  
‘Training courses can improve pharmacist’s 
knowledge regarding falsified medicines’ (state-
ment 6) was supported by 80% of respondents with 
a narrow standard deviation (0.824) indicating con-
sensus around ‘Agree’. 
‘Listening to patients could help identify falsified 
medicines’ (statement 7) was supported by 62% of 
respondents. Listening to patients’ comments on 
clinical changes with a new batch of their medi-
cines may help combat counterfeiting (Wright and 
Nicholson, 2009). Counterfeit medicines are often first 
detected by patients and therefore it’s important to 
listen to them (MHPRA, Royal Pharmaceutical Society, & 
Dispensing Doctors’ Association, n.d.). 
‘The majority of my fellow pharmacists in the UK 
are confident regarding falsified medicines’ (state-
ment 8) The majority (58%) of respondents are un-
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certain about this statement, indicating that their 
colleagues might be just as ‘lost’ as they are. Simi-
larly, consensus around ‘disagree’ with an SD of 
0.853. 
‘I’m confident and capable in identifying falsified 
medicines’ (statement 9) was supported by only 
20% of respondents. Surprisingly, this statement 
has a higher SD than statement 8. This still indi-
cates a majority opinion of ‘disagree’ but reveals a 
self-effacing bias (i.e. respondent believes others are 
more capable) with only a few respondents having a 
self-serving bias.  
‘I’m constantly vigilant to encountering falsified 
medicines when checking prescriptions’ (statement 
10) was supported by 38% of respondents, with 42% 
disagreeing with it. Overall the mean settles at ‘un-
certain’, with the second largest SD spread around 
the mean. 
‘I have enough knowledge to identify falsified 
medicines’ (statement 11) was supported by 30% of 
respondents, indicating that 48% of respondents 
did not believe that they have enough knowledge to 
identify falsified medicines. This suggests that 
pharmacists are underprepared when it comes to 
encountering counterfeit medicines. 
The original 11 item scale had a Cronbach's alpha 
(a measure of internal consistency and reliability) of 
69.4%. However, after running a bivariate Pearson 
correlation on the scale, two items (statement 2 and 
3) were found to correlate by 0.768 indicating that 
they were measuring the same facet of construct. 
Hence by deleting statement 2, the empirical value 
of the scale was improved, which in turn improved 
the Cronbach's alpha to 72.2% (Cronbach's alpha 
based on standardized items 72.8%). A Cronbach's 
alpha above 70% indicates a ‘good’ internal con-
sistency and reliability of the scale. This validates 
collectively the scale.  
Hypothesis testing was done. Null hypothesis as-
sumed that ‘gender’ made no difference in pharma-
cist confidence and capability. A significant differ-
ence (p = 0.039 Mann-Whitney U test) was found to 
statement 9: 38% of male respondents felt more 
confident and capable compared to 6.4% of female 
respondents. This could be a source of gender bias.  
Similarly, the researcher hypothesized that work 
experience made no difference to the pharmacist's 
ability to make an intervention. A significant differ-
ence (p = 0.017 Kruskal-Wallis test) was found: Ex-
perienced pharmacists seem to ‘agree strongly’ with 
statement 5, indicating pharmacist's experience can 
disrupt the supply of falsified medicines.  
Similarly, the researcher hypothesized that 
number of working hours per week made no differ-
ence to the pharmacist's ability to make an inter-
vention. A significant difference was found to 
statement 5 (p = 0.035 Kruskal-Wallis test) where it 
examined perspectives regarding pharmacists’ in-
tervention that can prevent or disrupt the supply of 
falsified medicines. Those working 35-44 h were the 
smallest group that agreed (52.4%) compared to 
other working contracts. This indicates that full-
time, experienced pharmacists were more confident 
in their ability to detect and disrupt the supply of 
falsified medicines. 
DISCUSSION 
Due to the limited information on UK pharma-
cist’s opinion on falsified medications, results from 
the cross-sectional survey provide a unique per-
spective and extend the understanding of how prac-
ticing community pharmacists deal with these cir-
cumstances. However, a low response rate of 14% 
and a small sample size (n=50) may limit the gener-
alizability of the study findings. However, this pro-
vides an up-to-date snapshot of the current phar-
macy practice with respect to falsified medicines, 
which is under represented in the literature.  
A total of 74% of respondents believed that falsi-
fied medicines pose a significant problem to the 
profession. Pharmacists are in the unique position 
of being the last line of defense in identifying coun-
terfeit medications. Pharmacists already ensure that 
they order medications from legitimate sources, 
however, vigilance is always necessary. Possibly ed-
ucating their patients on the risk of purchasing 
online medicines from unknown/disreputable 
sellers could be a solution. Evidence and experience 
shows that patients trust their pharmacists and are 
compelled to ask questions when their medications 
appear different. As an example, in a 2004 survey of 
patients that queried their knowledge of counterfeit 
medications, most patients (64%) said they would 
tell a pharmacist if they suspected they received or 
purchased a counterfeit drug (National Consumers 
League, 2004). 
Barrett and Al-Mousawi A postal survey of pharmacist opinions regarding falsified medicines 
 
http://jppres.com/jppres  J Pharm Pharmacogn Res (2018) 6(4): 248 
 
It is unknown how many pharmacists can 
properly recognize physical differences of counter-
feit medications and whether they have adequate 
resources to help them overcome this barrier. A to-
tal of 84% of respondents believe the ‘lack of 
knowledge is a barrier’ and that 74% believe that a 
‘lack of resources is a barrier for detecting the pres-
ence of falsified medicines’. Many resources are 
available for medication identification (often used 
by specialist pharmacists in medicines information 
in major hospitals and pharmaceutical companies), 
but not all pharmacists may have access to these 
resources. In the UK, National Health Service 
(NHS) medicines information can help with these 
queries. The ‘lack of resources’ may indicate little or 
no governance consideration by commercial, na-
tionwide, pharmacy chains or independent phar-
macies. Simultaneously, the incentives to address 
this statistically improbable event is low for such 
commercial entities. Equally, it may be the case that 
individual respondents are not aware of the latest 
MHRA guidance regarding counterfeit medicines, 
medicines recall, updates to practice advice, licens-
ing changes, etc. Nonetheless, the prevalence of fal-
sified medicines is on the rise.  
This study also found that 76% strongly agreed 
or agreed that pharmacist’s intervention could pre-
vent falsified medicines form reaching the patient. 
Therefore, providing some basic training could as-
sist pharmacists in this vein. Training courses were 
also identified (80%) as a knowledge store to assist 
pharmacists in mitigating this risk. Pharmacy stu-
dents and schools of pharmacies could provide such 
training, perhaps via collaborations with national 
pharmacy organizations and patient-safety agen-
cies. Pharmacists should also be encouraged to sub-
scribe to the MHRA updates as a cost-free alterna-
tive to get current up-to-date information. 
CONCLUSIONS 
The study found that falsified medicines pose a 
small but significant and growing challenge to the 
pharmacy profession. It also found that respond-
ents believe that a lack of resources is a barrier in 
combating this problem. From the results, there is 
underutilization of the high street community 
pharmacists in identify falsified medications. Most 
community pharmacists agreed that a pharmacists’ 
intervention and their interaction with (listening 
to) patients may help in combating falsified medi-
cines.  
Improving pharmacist’s knowledge regarding 
falsified medicines via education programs such as 
continuing education could be developed. 
Healthcare professionals should report suspected 
cases of counterfeit medication to the MHRA and 
be alert to threats to the medicine supply chain. 
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